AR101504A1 - Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6 - Google Patents

Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6

Info

Publication number
AR101504A1
AR101504A1 ARP150102591A ARP150102591A AR101504A1 AR 101504 A1 AR101504 A1 AR 101504A1 AR P150102591 A ARP150102591 A AR P150102591A AR P150102591 A ARP150102591 A AR P150102591A AR 101504 A1 AR101504 A1 AR 101504A1
Authority
AR
Argentina
Prior art keywords
inhibitor
hydrates
prodrugs
solvates
crystals
Prior art date
Application number
ARP150102591A
Other languages
English (en)
Original Assignee
Acerta Pharma Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acerta Pharma Bv filed Critical Acerta Pharma Bv
Publication of AR101504A1 publication Critical patent/AR101504A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un método de tratamiento un cáncer, que comprende la coadministración a un mamífero que lo necesita de una o más composiciones que comprenden cantidades terapéuticamente efectivas de (I) inhibidor de la quinasa 4/6 dependiente de ciclina (CDK4/6) o una de sus sales, solvatos, hidratos, cocristales o profármacos farmacéuticamente aceptables y (II) un inhibidor de la tirosina quinasa de Bruton (BTK) o una de sus sales, solvatos, hidratos, cocristales o profármacos farmacéuticamente aceptables. Reivindicación 7: El método de acuerdo con una de las reivindicaciones 1 a 6, en donde el inhibidor de BTK se selecciona del grupo que consiste en: el grupo de fórmulas (1), y sus sales, cocristales, hidratos, solvatos o profármacos farmacéuticamente aceptables. Reivindicación 8: El método de acuerdo con la reivindicación 7, que también comprende la etapa de administración de una dosis terapéuticamente efectiva de un anticuerpo anti-CD20 seleccionado del grupo que consiste en rituximab, obinutuzumab, ofatumumab, veltuzumab, tositumomab, ibritumomab y sus fragmentos, derivados, conjugados, variantes, complejos rotulados con radioisótopos y biosimilares. Reivindicación 10: El método de acuerdo con cualquiera de las reivindicaciones 1 - 9, en donde el inhibidor de CDK4/6 es palbociclib de fórmula (2), de sus sales, cocristales, hidratos, solvatos o profármacos farmacéuticamente aceptables. Reivindicación 14: El método de acuerdo con una de las reivindicaciones 2 a 13, en donde el inhibidor de PI3K se selecciona del grupo que consiste en: el grupo de fórmulas (3), y sus sales, solvatos, hidratos, cocristales o profármacos farmacéuticamente aceptables. Reivindicación 34: Una composición que comprende cantidades terapéuticamente efectivas de (I) un inhibidor de la quinasa 4/6 dependiente de ciclina (CDK4/6) o una de sus sales, solvatos, hidratos, cocristales o profármacos farmacéuticamente aceptables y (II) un inhibidor de la tirosina quinasa de Bruton (BTK) o una de sus sales, solvatos, hidratos, cocristales o profármacos farmacéuticamente aceptables, para usar en el tratamiento de cáncer. Reivindicación 49: La composición de acuerdo con la reivindicación 48, en donde el inhibidor de JAK-2 se selecciona del grupo que consiste en ruxolitinib: de fórmula (4), pacritinib: de fórmula (5), y sus sales, cocristales, hidratos, solvatos o profármacos farmacéuticamente aceptables.
ARP150102591A 2014-08-11 2015-08-11 Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6 AR101504A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462035806P 2014-08-11 2014-08-11
US201462088371P 2014-12-05 2014-12-05
US201562115512P 2015-02-12 2015-02-12
US201562181163P 2015-06-17 2015-06-17

Publications (1)

Publication Number Publication Date
AR101504A1 true AR101504A1 (es) 2016-12-21

Family

ID=53969402

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102591A AR101504A1 (es) 2014-08-11 2015-08-11 Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6

Country Status (4)

Country Link
US (2) US20170224819A1 (es)
AR (1) AR101504A1 (es)
TW (1) TW201618773A (es)
WO (1) WO2016024232A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3179991T (lt) 2014-08-11 2021-11-10 Acerta Pharma B.V. Terapiniai btk inhibitoriaus ir bcl-2 inhibitoriaus deriniai
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2017197904A2 (zh) * 2016-05-08 2017-11-23 上海诚妙医药科技有限公司 帕布昔利布的新晶型及其制备方法及其用途
AU2017268839A1 (en) * 2016-05-27 2018-11-29 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat B-cell proliferative disorders
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
JP2020530282A (ja) * 2017-07-07 2020-10-22 アレナ ファーマシューティカルズ， インコーポレイテッド 組換えウリカーゼ酵素
PE20210121A1 (es) 2018-01-08 2021-01-19 G1 Therapeutics Inc Regimenes de dosificacion superior de g1t38
US20210380710A1 (en) * 2018-05-29 2021-12-09 WuXi Biologics Ireland Limited A novel anti-cd3/anti-cd20 bispecific antibody
JP2021534114A (ja) * 2018-08-14 2021-12-09 エムイーアイ ファーマ，インク． 併用療法
CN111377929A (zh) * 2018-12-28 2020-07-07 南京艾德凯腾生物医药有限责任公司 一种可用于治疗白血病阿卡替尼(Acalabrutinib)制备的方法
CN113840608B (zh) * 2019-05-30 2023-11-14 江苏恒瑞医药股份有限公司 Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途
WO2020263822A1 (en) * 2019-06-25 2020-12-30 San Diego State University Foundation Selective btk irreversible inhibitors
JP2023529313A (ja) * 2020-05-26 2023-07-10 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低悪性度ｂ細胞リンパ腫における循環ｂ細胞亜集団
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062236A1 (en) * 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
AU2004282219C1 (en) 2003-10-15 2009-12-17 Osi Pharmaceuticals, Inc. Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors
AU2005245875C1 (en) 2004-05-13 2017-08-31 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US8153630B2 (en) 2004-11-17 2012-04-10 Miikana Therapeutics, Inc. Kinase inhibitors
KR101374553B1 (ko) 2004-11-18 2014-03-17 신타 파마슈티칼스 코프. Ｈｓｐ90 활성을 조절하는 트리아졸 화합물
PL1858644T3 (pl) 2005-02-18 2013-05-31 Univ Hong Kong Polytechnic Sposób asymetrycznego hydrosililowania ketonów
ES2535854T3 (es) 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Compuestos de pirazol sustituidos
KR101499594B1 (ko) 2005-11-16 2015-03-09 씨티아이 바이오파마 코포레이션 산소가 결합된 피리미딘 유도체
UA116187C2 (uk) 2005-12-13 2018-02-26 Інсайт Холдінгс Корпорейшн ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
WO2007077435A1 (en) 2005-12-30 2007-07-12 Astex Therapeutics Limited Pharmaceutical compounds
EP2532235A1 (en) 2006-09-22 2012-12-12 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
KR20150043565A (ko) 2007-03-12 2015-04-22 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
JP5527761B2 (ja) 2007-03-23 2014-06-25 アムジエン・インコーポレーテツド 複素環化合物およびそれの使用
AU2008262291A1 (en) 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
ES2714092T3 (es) 2007-06-13 2019-05-27 Incyte Holdings Corp Uso de sales del inhibidor de quinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
PT2288610T (pt) 2008-03-11 2016-10-17 Incyte Holdings Corp Derivados de azetidina e de ciclobutano como inibidores de jak
JP2011526299A (ja) 2008-06-27 2011-10-06 アビラ セラピューティクス， インコーポレイテッド ヘテロアリール化合物およびそれらの使用
CN102227219A (zh) 2008-11-26 2011-10-26 迈卡纳治疗股份有限公司 取代的吡唑化合物
PA8851101A1 (es) 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
ES2453474T3 (es) 2009-02-06 2014-04-07 Nippon Shinyaku Co., Ltd. Derivados de aminopirazina y medicamento correspondiente
DK2401267T3 (en) 2009-02-27 2014-03-10 Ambit Biosciences Corp JAK-kinase modulating quinazoline derivatives AND THEIR APPLICATION IN PROCESSES
UA106078C2 (uk) 2009-05-22 2014-07-25 Інсайт Корпорейшн 3-[4-(7H-ПІРОЛО[2,3-d]ПІРИМІДИН-4-ІЛ)-1H-ПІРАЗОЛ-1-ІЛ]ОКТАН- АБО ГЕПТАННІТРИЛ ЯК JAK-ІНГІБІТОРИ
EP2470534A4 (en) 2009-08-24 2013-02-27 Merck Sharp & Dohme INHIBITION OF JAK BLOCKES TOXICITIES ASSOCIATED WITH INTERFERENCE RNA
EP2473510B1 (en) 2009-09-03 2014-07-23 Bristol-Myers Squibb Company Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
EP2486041B1 (en) 2009-10-09 2013-08-14 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
ES2593256T3 (es) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
AU2011289604C1 (en) 2010-08-10 2016-04-21 Celgene Avilomics Research, Inc. Besylate salt of a BTK inhibitor
WO2012020787A1 (ja) 2010-08-11 2012-02-16 日本新薬株式会社 悪性リンパ腫治療剤
WO2012020786A1 (ja) 2010-08-11 2012-02-16 日本新薬株式会社 医薬組成物
EP2611794A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
WO2012030944A2 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinoline and isoquinoline compounds and methods of use thereof
AU2011296074B2 (en) 2010-09-01 2015-06-18 Ambit Biosciences Corporation An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
CA2817564A1 (en) 2010-11-18 2012-05-24 Ronald K. Blackman Preselection of subjects for therapeutic treatment based on hypoxic status
WO2012068487A1 (en) 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
AU2011335882B2 (en) 2010-12-03 2016-03-10 Ym Biosciences Australia Pty Ltd Treatment of JAK2-mediated conditions
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
CN103391779A (zh) 2011-02-24 2013-11-13 辛塔医药品有限公司 使用hsp90抑制性化合物的前列腺癌治疗
WO2012116247A1 (en) 2011-02-25 2012-08-30 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
CA2760174A1 (en) 2011-12-01 2013-06-01 Pharmascience Inc. Protein kinase inhibitors and uses thereof
ES2590144T3 (es) 2011-04-04 2016-11-18 Pharmascience Inc. Inhibidores de proteína quinasa
WO2012155063A1 (en) 2011-05-11 2012-11-15 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound
MX355728B (es) 2011-05-17 2018-04-27 Univ California Inhibidores de cinasas.
EP2714039A1 (en) 2011-05-23 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
WO2012162372A1 (en) 2011-05-24 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
WO2012162584A1 (en) 2011-05-26 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with chk inhibitors
US8906885B2 (en) 2011-07-07 2014-12-09 Synta Pharmaceuticals Corp. Treating cancer with HSP90 inhibitory compounds
WO2013010869A1 (en) 2011-07-19 2013-01-24 Msd Oss B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors
TWI565709B (zh) 2011-07-19 2017-01-11 英菲尼提製藥股份有限公司 雜環化合物及其用途
LT2734522T (lt) * 2011-07-19 2019-02-11 Merck Sharp & Dohme B.V. 4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai kaip btk-inhibitoriai
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
WO2013028505A1 (en) 2011-08-19 2013-02-28 Synta Pharmaceuticals Corp. Combination cancer therapy of hsp90 inhibitor with antimetabolite
WO2013032591A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US8628752B2 (en) 2011-10-28 2014-01-14 Synta Pharmaceuticals Corp. Methods of identifying HSP90 inhibitors with less ocular toxicity
CA2853806C (en) 2011-11-02 2020-07-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
AU2012339679A1 (en) 2011-11-14 2014-06-12 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with BRAF inhibitors
PL2786996T3 (pl) 2011-11-29 2017-01-31 Ono Pharmaceutical Co., Ltd. Chlorowodorowa pochodna purynonu
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013155347A1 (en) * 2012-04-11 2013-10-17 Izumi Raquel Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
JP2015516439A (ja) 2012-05-10 2015-06-11 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０阻害化合物で癌を治療すること
WO2013170182A1 (en) 2012-05-11 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound
JP2015525063A (ja) 2012-05-16 2015-09-03 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づくｈｓｐ９０インヒビターでの治療のための被験者の予備選択
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
BR112015003153A2 (pt) 2012-08-17 2017-07-04 Concert Pharmaceuticals Inc baricitinib deuterado
MX367918B (es) 2013-04-25 2019-09-11 Beigene Ltd Compuestos heterociclicos fusionados como inhibidores de proteina quinasa.
US20150005277A1 (en) 2013-06-28 2015-01-01 Beigene, Ltd. Protein Kinase Inhibitors and Uses Thereof
AU2014339816B2 (en) * 2013-10-25 2020-05-28 Pharmacyclics Llc Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy
US10314842B2 (en) * 2013-12-02 2019-06-11 Cornell University Methods for treating B cell proliferative disorders
CA2931431A1 (en) * 2013-12-05 2015-06-11 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
WO2015193740A2 (en) * 2014-06-17 2015-12-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor

Also Published As

Publication number Publication date
US20170224819A1 (en) 2017-08-10
US20180250400A1 (en) 2018-09-06
WO2016024232A1 (en) 2016-02-18
TW201618773A (zh) 2016-06-01

Similar Documents

Publication Publication Date Title
AR101504A1 (es) Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6
NI201900062A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CL2023000848A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
CR20190361A (es) Dendrímeros terapéuticos
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
PE20171241A1 (es) Terapias de combinacion para el tratamiento de canceres
CL2014002062A1 (es) Compuesto de moleculas pequeñas que inhiben cdk8 y cdk19, excluyendo cortistatina a y otros; formulacion farmceutica; un método para tratar a un mamifero que tiene una enfermedad relacionada con cdk1 como e. de alzheimer, otras demencias, amiloidosis, y un metodo para quimioproteger un paciente que padece cancer de ovario o mama, entre otros.
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
AR108889A1 (es) Combinaciones para el tratamiento del cáncer
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CY1122763T1 (el) Νεες ενωσεις ιμιδαζοπυριδαζινης και η χρηση αυτων
AR100431A1 (es) Compuestos de pladienolida piridina y métodos de uso
BR112017004589A2 (pt) composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
CO2020013968A2 (es) Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer
CL2020000271A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr y un inhibidor de quinasa dependiente de ciclina.
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
CO2018013828A2 (es) Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
BR112015023078A2 (pt) inibidores de pirrolopirimindina cdk9 quinase
AR105400A1 (es) Inhibidores de jak1

Legal Events

Date Code Title Description
FB Suspension of granting procedure